Senseonics Holdings earnings release, August 6, 2026

Senseonics Holdings, Inc. (SENS) · Form 8-K, Item 2.02 · Filed · SEC filing

​

Senseonics Holdings, Inc. Reports Second Quarter 2026 Financial Results

GERMANTOWN, MD., August 6, 2026

(GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced second quarter 2026 financial results and provided a business update.

Recent Highlights & Accomplishments

“This was the strongest quarter in Senseonics’ history, achieving record revenue and expanded margins, while integrating European commercial operations, building Eon Care, and advancing our Gemini and Freedom development programs,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. “Revenue grew approximately 120% year-over-year, and we delivered gross margin above our guided range for the second consecutive quarter, which validates the decision we made to bring our commercial organization fully in-house. The European commercial CGM organization is now integrated into Senseonics, and Eon Care continues to scale as one of our most important growth drivers. Given our momentum, we’re raising our full-year revenue and margin guidance. We’re not just growing the business — we’re redefining what a CGM can be.”

“Our commercial momentum continues to build, with strong U.S. direct-to-consumer results, now representing our largest source of new patients, improved productivity across our health care provider channel, and continued expansion of Eon Care,” added Brian Hansen, Chief Commercial Officer of Senseonics. “We were also encouraged by continued uptake of Eversense 365 in combination with the twiist

ä

Automated Insulin Delivery system. We look forward to continuing to drive performance with Eversense global commercialization now fully under Senseonics control.”

​

Second Quarter 2026 Results:

Total revenue for the second quarter of 2026 was $14.5 million, an increase of approximately 120% compared to $6.6 million for the second quarter of 2025. U.S. revenue was $12.6 million for the second quarter of 2026, an increase of more than 150% compared to $4.9 million for the second quarter of 2025, and revenue outside the U.S. was $1.9 million compared to $1.7 million in the prior year period, an increase of approximately 12%, reflecting the timing of tender updates in Europe as the Company continued its commercial transition from Ascensia. The Company expects this timing dynamic to normalize in the third and fourth quarters, with Europe still expected to represent approximately 20% of full-year revenue.

Second quarter 2026 gross profit was $8.6 million, representing gross margin of approximately 59%, compared to gross profit of $3.1 million, or 47% gross margin, for the second quarter of 2025.

Second quarter 2026 research and development expenses were $11.6 million, compared to $7.7 million for the second quarter of 2025, reflecting Gemini clinical and ongoing development of Freedom.

Second quarter 2026 selling, general and administrative expenses were $32.9 million, compared to $9.7 million for the second quarter of 2025, related primarily to the commercial integration and European transition.

Net loss was $36.7 million, or $0.63 loss per share, in the second quarter of 2026 compared to net loss of $14.5 million, or $0.36 loss per share, in the second quarter of 2025.

As of June 30, 2026, cash, restricted cash, and cash equivalents totaled $143.0 million, and outstanding indebtedness, including accrued interest, was $55.5 million, reflecting the more than $100 million raised in the second quarter through the equity offering and the amended Hercules Capital credit facility.

Full Year 2026 Financial Outlook

Senseonics is raising its full-year 2026 global net revenue guidance to $62 million to $66 million from $60 million to $64 million, representing year-over-year growth of 76% to 87%, and is raising its full-year gross margin guidance to a range of 58% to 61% from its prior range of 55% to 58%. The Company’s outlook continues to reflect the ongoing roll-out of Eversense 365 outside the United States, planned direct-to-consumer marketing investment, the status of other sales and marketing initiatives, and utilization of the patient assistance programs for Eversense 365.

Conference Call Information

Management will hold a conference call to review the Company’s second quarter 2026 performance starting today at 4:30 p.m. (Eastern Time). The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics’ website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-800-343-5172 (US/Canada) or 1-203-518-9856 (International), passcode SENSQ2, approximately five to ten minutes prior to start time.

​

​

About Senseonics

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the design, development and commercialization of glucose monitoring products to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM system Eversense®

365 and Eversense®

E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

​

About Eversense... (truncated)or Eversense 365 and one time per day after day 21 for Eversense E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see https://www.eversensediabetes.com/safety-info/.

Forward Looking Statements

Financial statements

Income Statement

Three Months Ended — (in thousands, except share and per share data)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Six Months Ended – June 30, – 2026Six Months Ended – June 30, – 2025
Revenue, net12,6753,22322,0165,033
Revenue, net - related parties1,8083,4264,1787,873
Total revenue14,4836,64926,19412,906
Cost of sales5,9243,52810,6958,280
Gross profit8,5593,12115,4994,626
Expenses:Research and development expenses11,6397,71520,25015,014
Expenses:Selling, general and administrative expenses32,9089,72963,08317,423
Expenses:Operating loss-35,988-14,323-67,834-27,811
Other income (expense), net:Interest income1,0329731,7741,648
Other income (expense), net:Interest expense-1,600-1,145-2,792-2,574
Other income (expense), net:Other expense-149-6-186-23
Other income (expense), net:Total other income (expense), net-717-178-1,204-949
Other income (expense), net:Net Loss-36,705-14,501-69,038-28,760
Other comprehensive lossUnrealized (loss) gain on marketable securities-6226-12323
Other comprehensive lossOther comprehensive (loss) gain-6226-12323
Other comprehensive lossTotal comprehensive loss-36,767-14,475-69,161-28,737
Other comprehensive lossBasic net loss per common share-0.63-0.36-1.33-0.75
Other comprehensive lossBasic weighted-average shares outstanding57,842,71340,668,24551,910,00638,319,113
Other comprehensive lossDiluted net loss per common share-0.63-0.36-1.33-0.75
Other comprehensive lossDiluted weighted-average shares outstanding57,842,71340,668,24551,910,00638,319,113

Balance Sheet

December 31, — (in thousands, except share and per share data)

June 30, – 2026 – (unaudited)December 31, – 2025
Current assets:Cash and cash equivalents44,75340,234
Current assets:Restricted cash315315
Current assets:Short term investments, net97,90653,796
Current assets:Accounts receivable, net9,1376,807
Current assets:Accounts receivable, net - related parties1,1325,312
Current assets:Inventory, net8,4586,703
Current assets:Prepaid expenses and other current assets4,7554,366
Current assets:Total current assets166,456117,533
Current assets:Deposits and other assets6,0594,536
Current assets:Property, equipment and intangible assets, net4,3204,200
Current assets:Total assets176,835126,269
Current liabilities:Accounts payable4,8244,059
Current liabilities:Accrued expenses and other current liabilities16,03215,091
Current liabilities:Accrued expenses and other current liabilities, related parties3,8235,198
Current liabilities:Total current liabilities24,67924,348
Current liabilities:Long-term debt and notes payables, net55,80835,586
Current liabilities:Non-current operating lease liabilities6,0355,289
Current liabilities:Total liabilities86,52265,223
Stockholders’ equity:Common stock, $0.001 par value per share; 140,000,000 and 70,000,000 shares authorized as of June 30, 2026 and December 31, 2025, respectively; 52,864,750 shares and 41,265,778 shares issued and outstanding as of June 30, 2026 and December 31, 20255341
Stockholders’ equity:Additional paid-in capital1,176,3391,077,923
Stockholders’ equity:Accumulated other comprehensive income-5469
Stockholders’ equity:Accumulated deficit-1,086,025-1,016,987
Stockholders’ equity:Total stockholders’ equity90,31361,046
Stockholders’ equity:Total liabilities and stockholders’ equity176,835126,269
Full release

Any statements in this press release about future expectations, plans and prospects for Senseonics, including the revenue and gross margin guidance under the heading “Full Year 2026 Financial Outlook,” statements regarding the performance of Senseonics and/or Eversense, the expected normalization of European revenue timing dynamics and Europe representing approximately 20% of full-year revenue, the anticipated achievement of our 100-nurse Eon Care year-end goal, the ongoing commercial transition and roll-out of Eversense 365 in Europe, including the timing of tender updates, the expanded compatibility of Eversense 365 with automated insulin delivery systems, the future demand for Eversense, and other statements containing the words “believe,” “expect,” “intend,” “may,” “projects,” “will,” “planned,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks and uncertainties related to the continued commercial transition and roll-out of Eversense 365 in the European Union, including the timing of tender updates; risks related to the pace of Eon hiring and network scaling; uncertainties in insurer, regulatory and administrative processes and decisions; uncertainties in finalizing integration and commercial terms and coordination with health systems and other collaboration partners and third parties; uncertainties inherent in the ongoing commercialization and expansion of the Eversense product and Senseonics’ and its partners’ activities; uncertainties relating to the current economic and regulatory/political environment, including the effects of tariffs; the Company’s ability to satisfy conditions for future borrowings under the Hercules facility; and such other factors as are set forth in the risk factors detailed in Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2025 and quarterly reports on Form 10-Q filed with the SEC under the heading “Risk Factors.” The forward-looking statements included in this press release represent Senseonics’ views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while

Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.

​

Senseonics Investor Contact

Jeremy Feffer

LifeSci Advisors investors@senseonics.com

​

Senseonics Holdings, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

​

​

​

Senseonics Holdings, Inc.

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

​

​

​

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Senseonics Holdings earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.